Aurobindo Pharma gets USFDA nod for anti-bacterial injections

New Delhi: Drug firm Aurobindo Pharma today said it has received final approvals from the US health regulator to manufacture and market Oxacillin for Injection used for treating bacterial infections in the American market.

The company has received final approvals from the US Food & Drug Administration (USFDA) to manufacture and market Oxacillin for Injection USP, packaged in 1g and 2g vials and Oxacillin for Injection USP 10g/vial pharmacy bulk package, Aurobindo Pharma said in a statement. The products are ready for launch, it added.

[caption id=“attachment_596273” align=“alignleft” width=“380”]  Aurobindo now has a total of 174 ANDA approvals. Agencies[/caption]

These abbreviated new drug applications (ANDAs) have been approved out of the company’s facility in Hyderabad and will be marketed and sold by its US subsidiary AuroMedics Pharma LLC, Aurobindo Pharma said.

More from Fwire

BCCI earned more than Rs 2,400 crore in IPL 2022, reveal documents Eight Russian judokas barred from world championships after Ukraine boycott

“Oxacillin for Injection USP is a sterile semi-synthetic penicillin (SSP) indicated in the treatment of infections caused by penicillinase producing staphylococci which have demonstrated susceptibility to the drug,” it added.

Aurobindo now has a total of 174 ANDA approvals, the company said. Shares of Aurobindo Pharma were today trading at Rs 195.55 apiece in the afternoon trade on BSE, up 1.53 percent from their previous close.

PTI